Indications, patient selection and timing of referral for lung transplantation

European Respiratory Journal

Volumn 22, Issue 5, 2003, Pages 845-852

  Glanville, A R ^a   Estenne, M ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Indications; Lung transplantation; Referral; Selection criteria

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CYSTIC FIBROSIS; DEATH; DISEASE SEVERITY; HEALTH CARE PERSONNEL; HOSPITAL ADMISSION; HUMAN; LUNG DISEASE; LUNG FIBROSIS; LUNG TRANSPLANTATION; ORGAN DONOR; PATIENT CARE; PATIENT REFERRAL; PATIENT SELECTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECIPIENT; RESOURCE MANAGEMENT; RESPIRATORY TRACT DISEASE; RISK BENEFIT ANALYSIS; SURVIVAL; TIME; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME;

CYSTIC FIBROSIS; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; PATIENT SELECTION; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS; REFERRAL AND CONSULTATION; TIME FACTORS;

EID: 0242491037     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00039003     Document Type: Article

References (81)

1. Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. J Heart Lung Transplant 1998; 17: 703-709.
2. Marshall SE, Kramer MR, Lewiston NJ, Starnes VA, Theodore J. Selection and evaluation of recipients for heart-lung and lung transplantation. Chest 1990; 98: 1488-1494.
3. Smith CM. Patient selection, evaluation, and preoperative management for lung transplant candidates. Clin Chest Med 1997; 18: 183-197.
4. Mannes GP, de Boer WJ, van der Bij W, Grevink RG, Koeter GH. Three hundred patients referred for lung transplantation. Experiences of the Dutch Lung Transplantation Program. Groningen Lung Transplantation Group. Chest 1996; 109: 408-413.
5. Hertz MI, Taylor DO, Trulock EP, et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant 2002; 21: 950-970.
6. Snell GI, De Hoyos A, Winton T, Maurer JR. Lung transplantation in patients over the age of 50. Transplantation 1993; 55: 562-566.
7. Leibowitz DW, Caputo AL, Shapiro GC, et al. Coronary angiography in smokers undergoing evaluation for lung transplantation: is routine use justified? J Heart Lung Transplant 1994; 13: 701-703.
8. Thaik CM, Semigran MJ, Ginns L, Wain JC, Dec GW. Evaluation of ischemic heart disease in potential lung transplant recipients. J Heart Lung Transplant 1995; 14: 257-266.
9. Hadjiliadis D, Tapson VF, Davis RD, Palmer SM. Prognostic value of serum carcinoembryonic antigen levels in patients who undergo lung transplantation. J Heart Lung Transplant 2001; 20: 1305-1309.
10. Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest 1996; 109: 1176-1183.
11. Shane E, Papadopoulos A, Staron RB, et al. Bone loss and fracture after lung transplantation. Transplantation 1999; 68: 220-227.
12. Dodd VA, Staron RB, Papadopoulos A, et al. Bone densitometry should be included in the evaluation of candidates for lung transplantation. J Transpl Coord 1999; 9: 119-123.
13. Kanasky WF Jr, Anton SD, Rodrigue JR, Perri MG, Szwed T. Baz MA. Impact of body weight on long-term survival after lung transplantation. Chest 2002; 121: 401-406.
14. Madill J, Gutierrez C, Grossman J, et al. Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation. J Heart Lung Transplant 2001; 20: 288-296.
15. Doershuk CF, Stern RC. Timing of referral for lung transplantation for cystic fibrosis: overemphasis on FEV1 may adversely affect overall survival. Chest 1999; 115: 782-787.
16. Snell GI, Bennetts K, Bartolo J, et al. Body mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation. J Heart Lung Transplant 1998; 17: 1097-1103.
17. Sood N, Paradowski LJ, Yankaskas JR. Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med 2001; 163: 335-338.
18. O'Brien G, Criner GJ. Mechanical ventilation as a bridge to lung transplantation. J Heart Lung Transplant 1999; 18: 255-265.
19. Madden BP, Kariyawasam H, Siddiqi AJ, Machin A, Pryor JA, Hodson ME. Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure. Eur Respir J 2002; 19: 310-313.
20. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
21. Jonas MM, Kelly DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-1713.
22. Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347: 284-287.
23. Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med 1999; 340: 1081-1091.
24. De Meester J, Smits JM, Persijn GG, Haverich A. Lung transplant waiting list: differential outcome of type of end-stage lung disease, one year after registration. J Heart Lung Transplant 1999; 18: 563-571.
25. Pierson RN, Milstone AP, Loyd JE, Lewis BH, Pinson CW, Ely EW. Lung allocation in the United States, 1995-1997: an analysis of equity and utility. J Heart Lung Transplant 2000; 19: 846-851.
26. Ouwens JP, Groen H, TenVergert EM, Koeter GH, de Boer WJ, van der Bij W. Simulated waiting list prioritization for equitable allocation of donor lungs. J Heart Lung Transplant 2002; 21: 797-803.
27. D'Armini AM, Callegari G, Vitulo P, et al. Risk factors for early death in patients awaiting heart-lung or lung transplantation: experience at a single European center. Transplantation 1998; 66: 123-127.
28. Dark JH. Priorities for lung transplantation. Lancet 1998; 351: 4-5.
29. Gabbay E, Dark JH, Wrightson N, Corris PA. Lung transplantation in patients with cystic fibrosis. Thorax 1996; 51: 1068.
30. Studer SM, Krishnan JA, Orens JB. Indications for lung transplant referral: physician attitudes. J Heart Lung Transplant 2002; 21: 716-717.
31. Geertsma A, Ten Vergert EM, Bonsel GJ, de Boer WJ, van der Bij W. Does lung transplantation prolong life? A comparison of survival with and without transplantation. J Heart Lung Transplant 1998; 17: 511-516.
32. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998; 351: 24-27.
33. De Meester J, Smits JM, Persijn GG, Haverich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant 2001; 20: 518-524.
34. Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002; 21: 226-232.
35. Liou TG, Adler FR, Cahill BC, et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 2001; 286: 2683-2689.
36. Aurora P, Whitehead B, Wade A, et al. Lung transplantation and life extension in children with cystic fibrosis. Lancet 1999; 354: 1591-1593.
37. Kesten S. Is survival that important? J Heart Lung Transplant 1998; 17: 651-653.
38. Maish AB. Priorities for lung transplantation among patients with cystic fibrosis. JAMA 2002; 287: 1524-1525.
39. Edelman JD, Kotloff RM. Lung transplantation. A disease-specific approach. Clin Chest Med 1997; 18: 627-644.
40. Cordova FC, Criner GJ. Surgery for chronic obstructive pulmonary disease: the place for lung volume reduction and transplantation. Curr Opin Pulm Med 2001; 7: 93-104.
41. Meyers BF, Patterson GA. Lung transplantation versus lung volume reduction as surgical therapy for emphysema. World J Surg 2001; 25: 238-243.
42. Bavaria JE, Pochettino A, Kotloff RM, et al. Effect of volume reduction on lung transplant timing and selection for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1998; 115: 9-18.
43. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001; 345: 1075-1083.
44. Waddell TK, Keshavjee S. Lung transplantation for chronic obstructive pulmonary disease. Semin Thorac Cardiovasc Surg 1998; 10: 191-201.
45. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317: 1309-1314.
46. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959-967.
47. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 680-685.
48. Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 961-966.
49. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203.
50. Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM, Horrocks AW, Egan JJ. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001; 164: 103-108.
51. Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163: 43-48.
52. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164: 2102-2106.
53. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155: 1699-1704.
54. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187-1191.
55. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998; 113: 1230-1234.
56. Augarten A, Akons H, Aviram M, et al. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatr Transplant 2001; 5: 339-342.
57. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153: 345-352.
58. Flume PA. Cystic fibrosis: when to consider lung transplantation? Chest 1998; 113: 1159-1161.
59. Maurer JR. Patient selection for lung transplantation. JAMA 2001; 286: 2720-2721.
60. Robinson W, Waltz DA. FEV(1) as a guide to lung transplant referral in young patients with cystic fibrosis. Pediatr Pulmonol 2000; 30: 198-202.
61. Tantisira KG, Systrom DM, Ginns LC. An elevated breathing reserve index at the lactate threshold is a predictor of mortality in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2002; 165: 1629-1633.
62. Aurora P, Prasad SA, Balfour-Lynn IM, Slade G, Whitehead B, Dinwiddie R. Exercise tolerance in children with cystic fibrosis undergoing lung transplantation assessment. Eur Respir J 2001; 18: 293-297.
63. Stanchina ML, Tantisira KG, Aquino SL, Wain JC, Ginns LC. Association of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation. J Heart Lung Transplant 2002; 21: 217-225.
64. Venuta F, Rendina EA, De Giacomo T, et al. Timing and priorities for cystic fibrosis patients candidates to lung transplantation. Eur J Pediatr Surg 1998; 8: 274-277.
65. Venuta F, Rendina EA, Rocca GD, et al. Pulmonary hemodynamics contribute to indicate priority for lung transplantation in patients with cystic fibrosis. J Thorac Cardiovasc Surg 2000; 119: 682-689.
66. Fraser KL, Tullis DE, Sasson Z, Hyland RH, Thornley KS, Hanly PJ. Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Chest 1999; 115: 1321-1328.
67. Homma A, Anzueto A, Peters JI, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. J Heart Lung Transplant 2001; 20: 833-839.
68. Hayllar KM, Williams SG, Wise AE, et al. A prognostic model for the prediction of survival in cystic fibrosis. Thorax 1997; 52: 313-317.
69. Sharma R, Florea VG, Bolger AP, et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001; 56: 746-750.
70. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166: 1550-1555.
71. Vizza CD, Yusen RD, Lynch JP, Fedele F, Alexander Patterson G, Trulock EP. Outcome of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2000; 162: 819-825.
72. Aurora P, Wade A, Whitmore P, Whitehead B. A model for predicting life expectancy of children with cystic fibrosis. Eur Respir J 2000; 16: 1056-1060.
73. Ciriaco P, Egan TM, Cairns EL, Thompson JT, Detterbeck FC, Paradowski LJ. Analysis of cystic fibrosis referrals for lung transplantation. Chest 1995; 107: 1323-1327.
74. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
75. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
76. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
77. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
78. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-492.
79. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-434.
80. Hoeper MM, Galie N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1209-1216.
81. D'Armini AM, Cattadori B, Monterosso C, et al. Pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension: hemodynamic characteristics and changes. Eur J Cardiothorac Surg 2000; 18: 696-702.